AMS:GLPG - Galapagos Nv Stock Price & Analysis

About Galapagos Nv (AMS:GLPG)

(AMS:GLPG) Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

GLPG Stock Price

Statistics Highlights (AMS:GLPG)

Shares Outstanding	65.65M	Beta	0.30
Public Float	40.32M	P/E Ratio	-
% Short of Float	-	Dividend (Yield)	-
Held by Insiders	25.64%	Ex-Dividend Date
Held by Institutions	26.74%	IPO Date	May 6, 2005

Explore More on "Statistics" Section

GLPG Financial Summary

|

	Dec 21	Dec 20	Dec 19
Revenue	€484.85M	€478.05M	€895.89M
EBITDA	€-76.71M	€-295.24M	€163.81M
Net Income	€-103.23M	€-305.44M	€149.85M
Total Assets	€5.19B	€5.72B	€6.07B
Total Cash	€2.23B	€2.14B	€1.86B
Total Debt	€	€	€

	Dec 21	Sep 21	Jun 21
Revenue	€166.99M	€64.19M	€139.77M
EBITDA	€69.99M	€-70.14M	€-30.77M
Net Income	€16.35M	€-64.61M	€-64.33M
Total Assets	€5.19B	€5.33B	€5.43B
Total Cash	€2.23B	€2.83B	€2.64B
Total Debt	€	€	€

GLPG Stock Price History

Galapagos Nv Annual Stock Price History

Year	Open	Close	Change
2021	€49.07	€65.50	33.50%
2021	€81.30	€49.07	-39.65%
2020	€185.20	€81.30	-56.10%

Galapagos Nv Daily Stock Price History

Date	Open	High	Low	Close	Change	Volume
Jun 17, 2022	€49.90	€52.26	€49.72	€51.92	1.45%	582.27K
Jun 14, 2022	€51.78	€52.44	€50.58	€51.18	-5.29%	227.97K
Jun 9, 2022	€54.26	€55.26	€53.72	€54.04	3.09%	217.11K

View More on "Price History" Section

(AMS:GLPG) Stock Price FAQs

What is today's stock price of Galapagos Nv (AMS:GLPG)?

The current stock price of Galapagos Nv (AMS:GLPG) is €65.50.
Today GLPG stock price opened at €65.72 after previous close of €65.20.
During the day, Galapagos Nv stock quote has varied from a low of €64.78 to a high of €66.22.

What is Galapagos Nv's 52-week change?

GLPG 52-week high stock quote is €69.10, which is 5.50% above the current share price.
The Galapagos Nv (AMS:GLPG) 52-week low stock price is €41.30, which is 36.90% below the current share price.
Galapagos Nv share price volatility (52-week beta) is 0.30.

Galapagos Nv (AMS:GLPG) FAQ

How Much is Galapagos nv Worth?

Galapagos nv's worth today based on market capitalisation is €3.84B

How much dividend does Galapagos nv Pay?

The current annualized dividend payout for GLPG stock is €0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Galapagos nv's "Dividend" Section

When is the next earnings date for Galapagos nv (AMS:GLPG)?

Galapagos nv is expected to report earnings on August 04 ,2022.
View More Details on Galapagos nv's 'Earnings' Section

What is Galapagos nv’s Price to Earning (PE) ratio?

GLPG stock also has a Price to Sales (P/S) ratio of 7.92.

What is the Galapagos nv's ticker?

Galapagos nv trades on the Euronext Amsterdam stock market in Netherlands under the ticker symbol "GLPG". Galapagos nv’s stock symbol can also be displayed as "AMS:GLPG".

When did GLPG go public?

Galapagos nv completed its initial public offering (IPO) on May 06 ,2005.

Who are the owners of Galapagos nv?

Galapagos nv (AMS:GLPG) is owned by 26.73% institutional shareholders and by 25.64% insiders. The rest is owned by the public.
Explore More Details on Galapagos nv's “Ownership” Section

Who are the key executives of Galapagos nv (GLPG)?

Galapagos nv's key executive team includes the following managers:

Mr. Bart Filius M.B.A., MBA, Pres, COO & Member of Management Board (1970)
Dr. Andre Hoekema, Chief Bus. Officer & Member of Management Board (1957)
Dr. Walid Abi-Saab, Chief Medical Officer & Member of Management Board (1965)
Mr. Michele Manto M.B.A., Chief Commercial Officer & Member of Management Board (NA)
Dr. Paulus A. Stoffels M.D., Ph.D., Chief Exec. Officer (1962)
Ms. Elizabeth Goodwin, VP of Investor Relations (NA)
Ms. Sofie Van Gijsel, Head of Investor Relations (NA)
Marieke Vermeersch, Head of Corp. Communication (NA)
John Montana, Managing Director of Argenta (NA)
Ms. Chantal Tasset, Head of Devel. (NA)

What is Galapagos nv’s Sector & Industry Classification?

Galapagos nv (AMS:GLPG) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Galapagos nv?

Currently the number of employees working for Galapagos nv is 1,309.

Where are Galapagos nv's Headquarters?

Galapagos nv (AMS:GLPG) is headquartered in Belgium.

What are Galapagos nv's Address and Phone Number?

Galapagos nv’s mailing address is Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800.
The company’s phone number is 32 1 534 29 00.

What is the official website for Galapagos nv?

Galapagos nv’s official website is http://www.glpg.com

Galapagos NV Stock (AMS:GLPG)